Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Achieve Life Sciences (ACHV) Receivables - Other (2016 - 2023)

Achieve Life Sciences (ACHV) has disclosed Receivables - Other for 9 consecutive years, with $111000.0 as the latest value for Q4 2023.

  • Quarterly Receivables - Other rose 5.71% to $111000.0 in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $111000.0 through Dec 2023, up 5.71% year-over-year, with the annual reading at $111000.0 for FY2023, 5.71% up from the prior year.
  • Receivables - Other for Q4 2023 was $111000.0 at Achieve Life Sciences, up from $83000.0 in the prior quarter.
  • The five-year high for Receivables - Other was $350000.0 in Q2 2023, with the low at $83000.0 in Q3 2023.
  • Average Receivables - Other over 3 years is $166666.7, with a median of $145000.0 recorded in 2022.
  • The widest YoY moves for Receivables - Other: up 11.82% in 2023, down 42.76% in 2023.
  • Achieve Life Sciences' Receivables - Other stood at $153000.0 in 2021, then plummeted by 31.37% to $105000.0 in 2022, then increased by 5.71% to $111000.0 in 2023.
  • Per Business Quant, the three most recent readings for ACHV's Receivables - Other are $111000.0 (Q4 2023), $83000.0 (Q3 2023), and $350000.0 (Q2 2023).